Plan for a Cooperative Study in the Evaluation of the Effectiveness of Chemotherapeutic Agents in the Treatment of a Broadspectrum of Malignant Diseases in Adults

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrentl ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial [PMC2836168; PMID20044128]

Maurie Markman;James Moon;S Wilczynski;AM Lopez;KM Rowland;DP Michelin;V Lanzotti;G Anderson;D Alberts Gynecologic Oncology 116(3):323-325

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of ititial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) [PMC2276605; PMID17949799]

DS Alberts;PY Liu;SP Wilczynski;MC Clouse;AM Lopez;DP Michelin;VJ Lanzotti;M Markman Gynecologic Oncology 108:90-94

Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200

DS Alberts;PY Liu;S Wilczynski;M Clouser;A Lopez;M Lange;V Lanzotti;M Markman Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#5551